



# Paracetamol for Patent Ductus Arteriosus Closure: High Osmolality of Enteral Form and Spontaneous Intestinal Perforation

Amrit Tuteja<sup>1</sup> · Femitha Pournami<sup>1</sup>  · Arif Abdulsalam Kolisambeevi<sup>1</sup> · Anand Nandakumar<sup>1</sup> · Jyothi Prabhakar<sup>1</sup> · Naveen Jain<sup>1</sup>

Received: 19 May 2020 / Accepted: 7 July 2020 / Published online: 16 July 2020  
© Dr. K C Chaudhuri Foundation 2020

*To the Editor:* Efficacy of oral and intravenous paracetamol for hemodynamically significant patent ductus arteriosus (hsPDA) is comparable to older agents; with lesser complications [1]. It becomes imperative for clinicians to be aware of problems that may be associated with it. We report a case of intestinal perforation after oral paracetamol for hsPDA. We believe that the osmolality of the formulation may be partially responsible.

Baby S was delivered at 28 wk with 850 g weight for abnormal umbilical artery dopplers. Parenteral nutrition was initiated and standard feed regimens were followed (mother's own milk). On day 6 she reached 100 ml/kg/d of feeds. On day 7, echo confirmed the presence of hsPDA. Standard recommended dose of oral paracetamol 15 mg/kg/dose (Calpol drops 100 mg/ml, Glaxosmithkline) every 8 h for 3 d was administered by orogastric tube with the scheduled feeds. Around 36 h later, she developed abdominal distension and bilious aspirates. Inotropes were required. X-ray evidence of free air in the peritoneum required a bedside peritoneal drain insertion. Laparotomy done 48 h later revealed multiple large perforations in the descending colon, with rest of the bowel uncompromised. Colostomy was performed. Subsequently, feeds could be escalated up to 90 ml/kg/d. Alas on day 26 of life, she developed features of sepsis. Blood culture was reported positive for *Serratia marsescens*. In spite of appropriate antibiotics and intensive care, baby succumbed on day 28 of life.

Safety studies of paracetamol for hsPDA have focused on reporting the expected hepatotoxicity, with elevated bilirubin and hepatic enzymes typically occurring 3 to 5 d into the course [2]. Indian studies have reported no serious adverse events [3]. A recent study has noted 20% incidence of

spontaneous intestinal perforation (SIP). It is difficult to evaluate the relationship between paracetamol and necrotising enterocolitis or SIP [4].

Drug osmolality is an often overlooked pharmacokinetic aspect, when therapy is instituted enterally. A literature review of the topic revealed shocking revelations of extremely high osmolality of several drugs that are quite often used in neonatal practice. Osmolality of 330–350 mOsm/kg H<sub>2</sub>O is considered appropriate for enteral administration. Oral paracetamol was found to have osmolality above 7000 mosm/kg H<sub>2</sub>O [5].

Further use of these medications may need attention to formulations suitable for use in preterm neonates.

## Compliance with Ethical Standards

**Conflict of Interest** None.

## References

1. Ohlsson A, Shah PS. Paracetamol (acetaminophen) for patent ductus arteriosus in preterm or low birth weight infants. *Cochrane Database Syst Rev.* 2020;1:CD010061.
2. Terrin G, Conte F, Oncel MY, et al. Paracetamol for the treatment of patent ductus arteriosus in preterm neonate: a systematic review and meta analysis. *Arch Dis Child Fetal Neonatal Ed.* 2016;101:F127–36.
3. Dash SK, Kabra NS, Avasthi BS, Sharam SR, Padhi P, Ahmed J. Enteral paracetamol or intravenous indomethacin for closure of patent ductus arteriosus in preterm neonates: a randomized controlled trial. *Indian Pediatr.* 2015;52:573–8.
4. Luecke CM, Liviskie CJ, Zeller BN, Vesoulis ZA, McPherson C. Acetaminophen for patent ductus arteriosus in extremely low-birth-weight neonates. *J Pediatr Pharmacol Ther.* 2017;22:461–6.
5. Polo AF, Poy M, Bautista SC, Oliveras M, Salinas FC, Albert EH. Osmolality of oral liquid dosage forms to be administered to newborns in a hospital. *Farm Hosp.* 2007;31:311–4.

✉ Femitha Pournami  
femi\_shifas@yahoo.com

<sup>1</sup> Department of Neonatology, Kerala Institute of Medical Sciences, Trivandrum 695029 India